Yanagisawa Y
2nd Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
Nihon Jinzo Gakkai Shi. 1994 Oct;36(10):1095-102.
Tempocapril is a novel angiotensin-converting enzyme (ACE) inhibitor which is preferentially eliminated via the biliary tract. To examine whether it has a protective effect in diabetic nephropathy like conventional ACE inhibitors which are eliminated via the kidney, a study was performed in streptozotocin-induced diabetic rats for 8 months. Male Wistar rats were divided into 4 groups (control rats, diabetic rats treated with temocapril at the doses of 5 mg/l or 15 mg/l of drinking water, and untreated diabetic rats). There was no significant difference in the blood glucose levels of the 3 diabetic groups. Administration of temocapril at both doses of 5 mg/l and 15 mg/l significantly reduced the blood pressure as well as the urinary excretion of albumin and N-acetyl-beta-D-glucosaminidase. However, significant suppression of glomerular basement membrane hypertrophy was only induced by treatment with temocapril at the dose of 15 mg/l. Elevated glomerular filtration rate and filtration fraction in diabetic rats were decreased by tempocapril at the dose of 15 mg/l, but not significantly. These results indicate that tempocapril has a protective effect on diabetic nephropathy like conventional ACE inhibitors.
替莫卡普利是一种新型的血管紧张素转换酶（ACE）抑制剂，主要通过胆道排泄。为了研究它是否像通过肾脏排泄的传统ACE抑制剂那样对糖尿病肾病具有保护作用，我们对链脲佐菌素诱导的糖尿病大鼠进行了为期8个月的研究。雄性Wistar大鼠被分为4组（对照大鼠、分别饮用含5 mg/l或15 mg/l替莫卡普利的饮用水的糖尿病大鼠，以及未治疗的糖尿病大鼠）。3个糖尿病组的血糖水平没有显著差异。5 mg/l和15 mg/l剂量的替莫卡普利给药均显著降低了血压以及白蛋白和N-乙酰-β-D-氨基葡萄糖苷酶的尿排泄量。然而，仅15 mg/l剂量的替莫卡普利治疗可显著抑制肾小球基底膜肥大。15 mg/l剂量的替莫卡普利可降低糖尿病大鼠升高的肾小球滤过率和滤过分数，但效果不显著。这些结果表明，替莫卡普利像传统ACE抑制剂一样对糖尿病肾病具有保护作用。
